Chemistry:Emvistegrast

From HandWiki

Emvistegrast is an investigational new drug that as of 2026 was being developed by Gilead Sciences for the treatment of ulcerative colitis. It is an integrin alpha4/beta7 antagonist.[1][2]

References

  1. ↑ "Emvistagrast - Gilead Sciences - AdisInsight". adisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800063854. 
  2. ↑ "Emerging small molecules for ulcerative colitis: clinical advancements and trial insights". Expert Opinion on Emerging Drugs 31 (1–2): 37–54. 2026. doi:10.1080/14728214.2026.2680722. PMID 42251531. 

Further reading

  • "Pharmacokinetics, Safety, and Tolerability of GS-1427, an Oral Prodrug of a Potent and Selective α4β7 Integrin Inhibitor, in Healthy Participants.". Journal of Clinical Pharmacology 66 (3). March 2026. doi:10.1002/jcph.70177. PMID 41854177. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Emvistegrast&oldid=4584043"